TaiGen inks antibiotics deal in China

CLINICAL COOPERATION:TaiGen Biotechnology Co says it is moving into the lucrative Chinese antibiotics market, after signing a 20-year agreement with Zhejiang Medicine Co

By George Liao / Staff reporter

Citing Taiwan’s strength in research on diseases that affect only ethnic Chinese, Wong said that clinical trial programs carried out in conjunction with Chinese researchers would further benefit medical research in the field. He made the remark on the second day of a four-day forum to review Taiwan’s policies on the biotech industry.